SOLENO THERAPEUTICS INC (SLNO) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-18

SOLENO THERAPEUTICS INC (SLNO) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-18. 1 Form 8-K material event filings were reported by SLNO in the last 90 days. InsiderAlpha tracks every SLNO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About SOLENO THERAPEUTICS INC (SLNO)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001484565

90-Day SEC Filing Activity

Form 4 filings (90d)	13
Form 8-K filings (90d)	1
Latest Form 4 filing	2026-05-18

Recent SLNO Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-18	Manning Meredith	Chief Commercial Officer	D — Derivative transaction	64.5K	—	—	SEC
2026-05-18	Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	583.7K	—	—	SEC
2026-05-18	Norrett Kevin	Chief Business Officer	D — Derivative transaction	17.8K	—	—	SEC
2026-05-18	Fulk Jennifer	CHIEF FINANCIAL OFFICER	D — Derivative transaction	39.2K	—	—	SEC
2026-05-18	Joshi Manher	Chief Development Officer	D — Derivative transaction	20.2K	—	—	SEC
2026-05-18	Huang Michael F.	Sr. VP of Clinical Development	D — Derivative transaction	39.8K	—	—	SEC
2026-05-18	Sinclair Andrew	Insider	D — Derivative transaction	10.5K	—	—	SEC
2026-05-18	Pauls Matthew	Insider	D — Derivative transaction	10.5K	—	—	SEC
2026-05-18	Hahn Mark W	Insider	D — Derivative transaction	10.0K	—	—	SEC
2026-05-18	Hirano Patricia C	SEE REMARKS	D — Derivative transaction	22.7K	—	—	SEC
2026-05-18	Bir Dawn Carter	Insider	D — Derivative transaction	17.0K	—	—	SEC
2026-05-18	Volck Birgitte	Insider	D — Derivative transaction	17.5K	—	—	SEC
2026-05-18	Yen Kristen	SEE REMARKS	D — Derivative transaction	37.6K	—	—	SEC
2026-03-27	Manning Meredith	Chief Commercial Officer	S — Open-market sale	2.1K	$31.04	$65K	SEC
2026-03-27	Huang Michael F.	Sr. VP of Clinical Development	S — Open-market sale	4.3K	$30.04	$128K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for SOLENO THERAPEUTICS INC (SLNO). Updated in real time as new filings are submitted to the SEC.

Most-Active SLNO Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Anish Bhatnagar	12	—
Yen Kristen	12	—
Hirano Patricia C	10	—
Sinclair Andrew	9	—
Volck Birgitte	8	—

Recent SLNO Form 8-K Material Events

2026-05-18 — Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 [SEC]
2026-04-07 — Item 8.01 · Clinical · negative [SEC]
Soleno Therapeutics voluntarily withdrew its European marketing authorization application (MAA) for VIOKAT (diazepoxide choline) for Prader-Willi syndrome treatment. The withdrawal was based on business and strategic considerations, though the company stated it preserves the abil
2026-04-06 — Item 1.01, 7.01, 9.01 · Acquisition · positive [SEC]
Soleno Therapeutics entered into a definitive merger agreement with Neurocrine Biosciences, whereby Neurocrine will acquire Soleno for $53.00 per share in an all-cash tender offer followed by a merger. This represents a significant premium acquisition of the biopharmaceutical com
2026-04-06 — Other · neutral [SEC]
Trading halt (T1) for SLNO. SLNO
2026-03-16 — Item 5.03, 9.01 · Other · neutral [SEC]
Soleno Therapeutics' Board of Directors approved and adopted Amended and Restated Bylaws effective March 16, 2026. The amendments updated advance notice provisions for stockholder proposals and nominations, reflected changes in Delaware law, included governance updates, and added

Recent Insider Filings

2026-05-18 — Yen Kristen (SEE REMARKS)
2026-05-18 — Volck Birgitte (Insider)
2026-05-18 — Sinclair Andrew (Insider)
2026-05-18 — Pauls Matthew (Insider)
2026-05-18 — Norrett Kevin (Chief Business Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SLNO insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

SLNO Insider Trading — FAQ

What is the latest insider trade for SLNO?: SOLENO THERAPEUTICS INC (SLNO) had 13 insider filings in the last 90 days, with the most recent on 2026-05-18. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying SLNO stock?: 0 insider purchases of SLNO were filed in the last 90 days.
How many insiders are selling SLNO stock?: 0 insider sales of SLNO were filed in the last 90 days.
Where can I see SLNO SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every SLNO SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live SLNO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.